TY - JOUR T1 - SARS-CoV-2-specific humoral and cellular immunity in renal transplant and haemodialysis patients treated with convalescent plasma JF - medRxiv DO - 10.1101/2020.12.09.20239673 SP - 2020.12.09.20239673 AU - Monika Lindemann AU - Adalbert Krawczyk AU - Sebastian Dolff AU - Margarethe Konik AU - Hana Rohn AU - Maximillian Platte AU - Laura Thümmler AU - Sina Schwarzkopf AU - Leonie Schipper AU - Maren Bormann AU - Lukas van de Sand AU - Marianne Breyer AU - Hannes Klump AU - Dietmar Knop AU - Veronika Lenz AU - Christian Temme AU - Ulf Dittmer AU - Peter A. Horn AU - Oliver Witzke Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/12/11/2020.12.09.20239673.abstract N2 - Background When patients with chronic kidney disease are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) they can face two specific problems: Virus-specific immune responses may be impaired and remdesivir, an antiviral drug described to shorten the time to recovery, is contraindicated. Antiviral treatment with convalescent plasma could be an alternative treatment option.Methods In this case series we present two kidney transplant recipients and two patients dependent on haemodialysis who were infected with SARS-CoV-2 and received convalescent plasma. Antibodies against the spike 1 protein of SARS-CoV-2 were determined sequentially by IgG ELISA and neutralization assay and specific T cell responses by interferon-gamma ELISpot.Results Prior to treatment, in three patients antibodies were undetectable by ELISA (ratio < 1.1), corresponding to low neutralizing antibody titers (≤ 1:40). One patient was also negative to the ELISpot and two showed weak responses. After convalescent plasma treatment we observed an increase of SARS-CoV-2-specific antibodies (IgG ratio and neutralization titer) and of specific T cell responses. After intermittent clinical improvement one kidney transplant recipient again developed typical symptoms at day 12 after treatment and received a second cycle of convalescent plasma treatment. Altogether, three patients clinically improved and could be discharged from hospital. However, one multimorbid female in her early eighties deceased.Conclusions Our data suggest that the success of convalescent plasma therapy may only be temporary in patients with chronic kidney disease; which requires an adaptation of the treatment regimen. Close monitoring after treatment is needed for this patient group.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Stiftung Universitaetsmedizin Essen (A.K.) and the Rudolf Ackermann Foundation (O.W.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the institutional review board of the University Hospital Essen, Germany (20-9256-BO for the patients and 20-9225-BO for the donors) and the study participants provided written informed consent. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on request from the corresponding author.SARS-CoV-2severe acute respiratory syndrome coronavirus 2CPconvalescent plasmaCOVID-19coronavirus 2019IFN-γinterferon-gammaPBMCperipheral blood mononuclear cellsS1spike 1 ER -